Oral Solubilization Technology: The SDD Performance Advantage
Successfully applied in 19 clinical trials
- 10-fold average increase in oral bioavailability over crystalline drug
- Applied in Phase 1, 2, and 3 clinical trials requiring scale-up from 1
kilogram to 10 metric tons
- Standardized tablet formulation developed
Successfully used for more than 200 compounds in preclinical animal testing
- Improved pharmacokinetics
- Improved efficacy
- Improved toxicology readouts
Demonstrated performance of compounds with a wide range of physicochemical
properties
Efficient systems in place to rapidly evaluate feasibility
- Low bulk drug requirements
- Rapid turnaround times for initial feasibility
|
